Woods M D, Shipston M J, Mullens E L, Antoni F A
Department of Pharmacology, University of Edinburgh, U.K.
Endocrinology. 1992 Dec;131(6):2873-80. doi: 10.1210/endo.131.6.1332850.
The utility of the established ACTH secreting mouse pituitary tumor cell line AtT20 for investigating early glucocorticoid inhibition was examined. Three different strains of the cell line D1, D16v, and D16:16, respectively, were analyzed. In initial studies CRF and phorbol esters were used as secretagogues to examine the properties of hormone secretion. In a perifusion system (cells in suspension) D1 cells failed to respond to the secretagogues, whereas both D16v and D16:16 cells were responsive. However, hormone release declined upon repeated exposure to secretagogue in both D16v and D16:16 cells and similar data were obtained when cells adhering to cover slips were perifused. In static incubation D16:16 cells gave more consistent results especially with respect to inhibition by glucocorticoids and were used in all subsequent studies. Synthetic glucocorticoids acting through the type II receptor inhibited CRF-induced ACTH release within 45 min; at 120 min, stimulated release was strongly (80-90%) suppressed. In contrast, no consistent inhibition by corticosterone could be found. In the presence of glycyrrhetinic acid, an inhibitor of 11 beta-hydroxysteroid dehydrogenase, a high concentration of corticosterone (10 microM) did produce a slight inhibition of ACTH release. Dexamethasone also inhibited ACTH release induced by the calcium channel activator compound (+)202-791. The accumulation of cAMP in response to CRF was not altered by dexamethasone. The inhibitory effect of synthetic glucocorticoids on ACTH release was prevented by blockers of messenger RNA (actinomycin D, dichlorobenzimidazole ribofuranoside) or protein (puromycin) biosynthesis, indicating the induction of new proteins. Immunoblotting for lipocortin I (annexin I) and chromogranin A revealed no induction by dexamethasone of any of these proteins in D16:16 cells. Messenger RNA encoding lipocortin I was not detectable and was not induced by treatment with dexamethasone in D16:16 cells. These data show that the AtT20 D16:16 strain is a useful model for early glucocorticoid action, which is mediated by type II receptors and involves the induction of new protein(s). Notably, induction of lipocortin I messenger RNA or protein could not be detected at a time when the inhibitory effect of glucocorticoids on stimulated hormone secretion was maximal.
研究了已建立的促肾上腺皮质激素(ACTH)分泌小鼠垂体瘤细胞系AtT20在研究早期糖皮质激素抑制作用方面的实用性。分别对该细胞系的三种不同菌株D1、D16v和D16:16进行了分析。在初步研究中,促肾上腺皮质激素释放因子(CRF)和佛波酯被用作促分泌剂来研究激素分泌的特性。在灌注系统(悬浮细胞)中,D1细胞对促分泌剂无反应,而D16v和D16:16细胞有反应。然而,在D16v和D16:16细胞中,反复暴露于促分泌剂后激素释放下降,当对贴附在盖玻片上的细胞进行灌注时也得到了类似的数据。在静态孵育中,D16:16细胞给出了更一致的结果,尤其是在糖皮质激素抑制方面,因此在所有后续研究中都使用了该细胞系。通过II型受体起作用的合成糖皮质激素在45分钟内抑制了CRF诱导的ACTH释放;在120分钟时,刺激释放被强烈抑制(80 - 90%)。相比之下,未发现皮质酮有一致的抑制作用。在11β - 羟基类固醇脱氢酶抑制剂甘草次酸存在的情况下,高浓度的皮质酮(10μM)确实对ACTH释放产生了轻微抑制。地塞米松也抑制了钙通道激活剂化合物(+)202 - 791诱导的ACTH释放。地塞米松未改变CRF刺激下cAMP的积累。合成糖皮质激素对ACTH释放的抑制作用被信使核糖核酸(放线菌素D、二氯苯并咪唑核糖苷)或蛋白质(嘌呤霉素)生物合成的阻滞剂所阻断,表明有新蛋白质的诱导。对lipocortin I(膜联蛋白I)和嗜铬粒蛋白A进行免疫印迹分析发现,地塞米松在D16:16细胞中未诱导这些蛋白质中的任何一种。在D16:16细胞中,未检测到编码lipocortin I的信使核糖核酸,用地塞米松处理也未诱导其产生。这些数据表明,AtT20 D16:16菌株是早期糖皮质激素作用的有用模型,其由II型受体介导,涉及新蛋白质的诱导。值得注意的是,在糖皮质激素对刺激的激素分泌的抑制作用最大时,未检测到lipocortin I信使核糖核酸或蛋白质的诱导。